Loading stock data…
Maravai LifeSciences Holdings, (MRVI)
$7.19-0.13 (-1.78%)
Market ClosedLast close Sep 8
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maravai LifeSciences Holdings, Inc. in the Healthcare sector is trading at $7.19 with a market capitalization of $2.7B. Wall Street consensus targets $7.30 (5 analysts), implying a +1.5% move over the next 12 months. The stock is currently 24% below its 52-week high of $9.42, remaining 59.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.44M↓ | $65.84M↑ | $49.87M↑ | $41.63M↓ | $47.40M |
| Gross Profit | $20.65M↓ | $33.70M↑ | $12.84M↑ | $5.66M↓ | $7.77M |
| Operating Income | -$15.12M↓ | $720,000↑ | -$22.53M↑ | -$33.59M↑ | -$35.83M |
| Net Income | -$12.42M↓ | -$3.73M↑ | -$35.68M↓ | -$25.56M↑ | -$39.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-37.82%
Volume
Today's trading volume
2.27M
Recent News
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a
Maravai (MRVI) Q2 2026 Earnings Call Transcript
Revenue grew 8.5% to $51.4 million as mRNA discovery demand surged.
Maravai LifeSciences Holdings, Inc. Q2 2026 Earnings Call Summary
Moby summary of Maravai LifeSciences Holdings, Inc.'s Q2 2026 earnings call
Maravai LifeSciences Q2 Earnings Call Highlights
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CE
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?